World's Best Scientists 2026 revealed!
Jan B. Vermorken

Jan B. Vermorken

D-Index & Metrics

Discipline name D-Index World Ranking Current World Ranking National Ranking Current National Ranking Publications Citations
Medicine 106 6456 6075 74 71 770 47345

Jan B. Vermorken publications per year

The chart shows the history of publications by Jan B. Vermorken between 1980 and 2025, highlighting the no. of papers published in each year and offering an overview of the publication velocity of this scholar. Jan B. Vermorken published across 46 years, from 1980 to 2025, averaging 17.5 papers a year. Output peaked at 46 publications in 2007. 8 of the 804 publications appeared in the last two years.

No. of publications
10 20 30 40
Bar chart. Horizontal axis: year, 1980 to 2025. Vertical axis: number of publications, 0 to 46. Peak 46 publications in 2007. 1980: 1 publication 1981: 0 publications 1982: 3 publications 1983: 2 publications 1984: 7 publications 1985: 2 publications 1986: 6 publications 1987: 6 publications 1988: 8 publications 1989: 8 publications 1990: 9 publications 1991: 16 publications 1992: 8 publications 1993: 23 publications 1994: 18 publications 1995: 22 publications 1996: 15 publications 1997: 19 publications 1998: 9 publications 1999: 33 publications 2000: 21 publications 2001: 24 publications 2002: 11 publications 2003: 27 publications 2004: 21 publications 2005: 24 publications 2006: 27 publications 2007: 46 publications 2008: 24 publications 2009: 35 publications 2010: 35 publications 2011: 33 publications 2012: 31 publications 2013: 26 publications 2014: 22 publications 2015: 28 publications 2016: 19 publications 2017: 30 publications 2018: 10 publications 2019: 19 publications 2020: 18 publications 2021: 19 publications 2022: 9 publications 2023: 22 publications 2024: 2 publications 2025: 6 publications
1980 2025

804 publications in total across all disciplines

View publications per year as a table
Jan B. Vermorken: publications per year, 1980 to 2025
Year Publications
1980 1
1981 0
1982 3
1983 2
1984 7
1985 2
1986 6
1987 6
1988 8
1989 8
1990 9
1991 16
1992 8
1993 23
1994 18
1995 22
1996 15
1997 19
1998 9
1999 33
2000 21
2001 24
2002 11
2003 27
2004 21
2005 24
2006 27
2007 46
2008 24
2009 35
2010 35
2011 33
2012 31
2013 26
2014 22
2015 28
2016 19
2017 30
2018 10
2019 19
2020 18
2021 19
2022 9
2023 22
2024 2
2025 6
Total 804
Download as CSV

Jan B. Vermorken publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Jan B. Vermorken sits on this spectrum.

No. of scientists
200 400 600 800
Bar chart with 86 bars. Horizontal axis: publications, 101–120 to 1,796+. Vertical axis: number of scientists, 0 to 922. Most scientists, 922, have 341–360 publications. The last bar groups every scientist with 1,796 publications or more. The highlighted bar, 761–780 publications, is where this scientist sits. 101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101–120 publications 1,796+

This scientist: 770 publications — 86th percentile

86% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

View publications distribution as a table
Number of Medicine scientists by publication count, Research.com 2026 ranking edition. Based on 20,134 ranked scientists.
Publications Scientists This scientist
101–120 5
121–140 26
141–160 73
161–180 155
181–200 230
201–220 363
221–240 487
241–260 545
261–280 722
281–300 768
301–320 834
321–340 895
341–360 922
361–380 838
381–400 861
401–420 918
421–440 806
441–460 771
461–480 751
481–500 713
501–520 617
521–540 610
541–560 537
561–580 504
581–600 509
601–620 396
621–640 386
641–660 371
661–680 340
681–700 336
701–720 307
721–740 259
741–760 230
761–780 228 770
781–800 217
801–820 204
821–840 186
841–860 177
861–880 155
881–900 139
901–920 145
921–940 116
941–960 133
961–980 91
981–1,000 96
1,001–1,020 77
1,021–1,040 70
1,041–1,060 63
1,061–1,080 77
1,081–1,100 49
1,101–1,120 54
1,121–1,140 49
1,141–1,160 51
1,161–1,180 35
1,181–1,200 39
1,201–1,220 26
1,221–1,240 37
1,241–1,260 36
1,261–1,280 27
1,281–1,300 32
1,301–1,320 28
1,321–1,340 17
1,341–1,360 30
1,361–1,380 28
1,381–1,400 17
1,401–1,420 21
1,421–1,440 15
1,441–1,460 12
1,461–1,480 12
1,481–1,500 18
1,501–1,520 14
1,521–1,540 17
1,541–1,560 15
1,561–1,580 6
1,581–1,600 2
1,601–1,620 12
1,621–1,640 11
1,641–1,660 8
1,661–1,680 5
1,681–1,700 5
1,701–1,720 10
1,721–1,740 12
1,741–1,760 14
1,761–1,780 6
1,781–1,795 5
1,796+ 100
Download as CSV

Jan B. Vermorken D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Jan B. Vermorken sits on this spectrum.

No. of scientists
250 500 750 1,000
Bar chart with 75 bars. Horizontal axis: D-Index, 70–71 to 217+. Vertical axis: number of scientists, 0 to 1,027. Most scientists, 1,027, have 82–83 D-Index. The last bar groups every scientist with 217 D-Index or more. The highlighted bar, 106–107 D-Index, is where this scientist sits. 70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70–71 D-Index 217+

This scientist: 106 D-Index — 69th percentile

69% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

View D-Index distribution as a table
Number of Medicine scientists by D-index, Research.com 2026 ranking edition. Based on 20,134 ranked scientists.
D-Index Scientists This scientist
70–71 226
72–73 391
74–75 574
76–77 730
78–79 891
80–81 972
82–83 1,027
84–85 1,003
86–87 960
88–89 970
90–91 922
92–93 839
94–95 808
96–97 779
98–99 668
100–101 611
102–103 630
104–105 513
106–107 541 106
108–109 445
110–111 429
112–113 399
114–115 393
116–117 318
118–119 302
120–121 287
122–123 255
124–125 256
126–127 252
128–129 230
130–131 179
132–133 168
134–135 163
136–137 159
138–139 134
140–141 134
142–143 118
144–145 109
146–147 106
148–149 74
150–151 79
152–153 80
154–155 87
156–157 57
158–159 74
160–161 69
162–163 60
164–165 53
166–167 39
168–169 42
170–171 32
172–173 39
174–175 40
176–177 28
178–179 19
180–181 23
182–183 31
184–185 18
186–187 20
188–189 22
190–191 13
192–193 21
194–195 12
196–197 12
198–199 14
200–201 15
202–203 13
204–205 10
206–207 8
208–209 4
210–211 12
212–213 11
214–215 10
216 4
217+ 98
Download as CSV

Overview

Jan B. Vermorken is affiliated with the University of Antwerp in Belgium and has contributed extensively to the field of medicine, with a particular focus on oncology. Their research spans several subfields including oncology, otorhinolaryngology, pulmonary and respiratory medicine, radiology, nuclear medicine and imaging, and surgery.

The scientist's work covers multiple main topics related to cancer studies. These include:

  • Head and Neck Cancer Studies
  • Cancer Immunotherapy and Biomarkers
  • Cancer Diagnosis and Treatment
  • Lung Cancer Treatments and Mutations
  • Head and Neck Surgical Oncology
  • Lung Cancer Research Studies
  • Cancer-related gene regulation

Vermorken has published in various venues with higher frequency in journals such as:

  • Frontiers in Oncology
  • Cancers
  • Oral Oncology
  • The Oncologist
  • International Journal of Radiation Oncology*Biology*Physics

Frequent collaborators in their research include:

  • Petr Szturz
  • Marc Peeters
  • Filip Lardon
  • An Wouters
  • Hannah Zaryouh

Notable recent publications by Jan B. Vermorken include:

  • De-Escalation After DE-ESCALATE and RTOG 1016: A Head and Neck Cancer InterGroup Framework for Future De-Escalation Studies, 2020, Journal of Clinical Oncology
  • SARS-CoV-2 and cancer: Are they really partners in crime?, 2020, Cancer Treatment Reviews
  • Emergency changes in international guidelines on treatment for head and neck cancer patients during the COVID-19 pandemic, 2020, Oral Oncology
  • Recent insights in the PI3K/Akt pathway as a promising therapeutic target in combination with EGFR-targeting agents to treat head and neck squamous cell carcinoma, 2021, Medicinal Research Reviews
  • The Right Partner in Crime: Unlocking the Potential of the Anti-EGFR Antibody Cetuximab via Combination With Natural Killer Cell Chartering Immunotherapeutic Strategies, 2021, Frontiers in Immunology

Best Publications

  • Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer

    Jan B. Vermorken;Ricard Mesia;Fernando Rivera;Eva Remenar

  • Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.

    Jan B. Vermorken;Eva Remenar;Carla Van Herpen;Thierry Gorlia

  • Open-Label, Uncontrolled, Multicenter Phase II Study to Evaluate the Efficacy and Toxicity of Cetuximab As a Single Agent in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Who Failed to Respond to Platinum-Based Therapy

    Jan B. Vermorken;José Trigo;Ricardo Hitt;Piotr Koralewski

  • Impact of Adjuvant Chemotherapy and Surgical Staging in Early-Stage Ovarian Carcinoma: European Organisation for Research and Treatment of Cancer–Adjuvant ChemoTherapy in Ovarian Neoplasm Trial

    J. Baptist Trimbos;Ignace Vergote;Giorgio Bolis;Jan B. Vermorken

  • European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion.

    E A Eisenhauer;W W ten Bokkel Huinink;K D Swenerton;L Gianni

  • Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial

    Jan B Vermorken;Anke M E Claessen;Harm van Tinteren;Helen E Gall

  • Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG).

    Gordon John Sampson Rustin;Ignace Vergote;Elizabeth Eisenhauer;Eric Pujade-Lauraine

  • Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: An European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874)

    N. S. Reed;C. Mangioni;H. Malmström;G. Scarfone

  • 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004).

    A du Bois;M Quinn;T Thigpen;J Vermorken

  • International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma.

    J Baptist Trimbos;Mahesh Parmar;Ignace Vergote;David Guthrie

  • Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial

    Jan B Vermorken;Jan Stöhlmacher-Williams;Irina Davidenko;Lisa Licitra

  • Advanced epithelial ovarian cancer: 1998 consensus statements.

    J. S. Berek;K. Bertelsen;A. Du Bois;M. F. Brady

  • Trabectedin Plus Pegylated Liposomal Doxorubicin in Recurrent Ovarian Cancer

    Bradley J. Monk;Thomas J. Herzog;Stanley B. Kaye;Carolyn N. Krasner

  • Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial

    Jean Pascal H Machiels;Robert I. Haddad;Jérôme Fayette;Lisa F. Licitra

  • Randomized trial comparing two combination chemotherapy regimens (CHAP-5 v CP) in advanced ovarian carcinoma.

    J P Neijt;W W ten Bokkel Huinink;M E van der Burg;A T van Oosterom

  • Optimal treatment for recurrent/metastatic head and neck cancer

    J. B. Vermorken;P. Specenier

  • Re: New Guidelines to Evaluate the Response to Treatment in Solid Tumors (Ovarian Cancer)

    Gordon J. S. Rustin;Michael Quinn;Tate Thigpen;Andreas du Bois

  • Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck A phase III study of the EORTC Head and Neck Cancer Cooperative Group

    M. Clavel;J. B. Vermorken;F. Cognetti;P. Cappelaere

  • Taxanes: A New Class of Antitumor Agents

    M. T. Huizing;V. H. Sewberath Misser;R. C. Pieters;W. W. ten Bokkel Huinink

  • European-Canadian randomized trial of Paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion

    Elizabeth A. Eisenhauer;Wim W. ten Bokkel Huinink;Kenneth D. Swenerton;Luca Gianni

Frequent Co-Authors

H.M. Pinedo
H.M. Pinedo Vrije Universiteit Amsterdam
Marc Peeters
Marc Peeters University of Antwerp
Lisa Licitra
Lisa Licitra University of Milan
Patrick Pauwels
Patrick Pauwels University of Antwerp
Jos H. Beijnen
Jos H. Beijnen Utrecht University
Eric Van Marck
Eric Van Marck University of Antwerp
Ezra E.W. Cohen
Ezra E.W. Cohen University of California, San Diego
Alfio Ferlito
Alfio Ferlito University of Udine
Alessandra Rinaldo
Alessandra Rinaldo University of Udine
Robert I. Haddad
Robert I. Haddad Harvard University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in medical careers but seeking flexible learning options, a range of online healthcare degrees are available. These programs help working professionals and career changers upskill quickly and affordably, providing alternative entry points into the medical field beyond traditional medical school.

Individuals aiming for healthcare leadership might consider the top cahme accredited mha programs. These online master’s degrees in healthcare administration are designed for those who want to lead in health systems, hospitals, or medical organizations.

Nurses can advance their credentials through online rn to bsn programs without clinicals. These programs offer academic flexibility and can be ideal for experienced RNs seeking to boost their qualifications from home.

Higher-level nursing degrees are also within reach. If time is a concern, the shortest online dnp program allows nurses to earn a Doctor of Nursing Practice efficiently. Cost-conscious students may prefer the cheapest dnp program to minimize tuition while maximizing their career options in advanced practice and leadership.

Best Scientists Citing Jan B. Vermorken

Trending Scientists

Recently Published Articles